Accelerating Medicines Partnership: Type 2 Diabetes Project

The Accelerating Medicines Partnership Type 2 Diabetes Project (AMP T2D), is a multi-sector, pre-competitive partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases. This program creates a T2D Knowledge Portal by building a database of DNA sequence, functional genomic and epigenomic, and clinical data from T2D studies with cardiac and renal complications data across roughly 150,000K+  individuals. The AMP T2D Knowledge Portal will house the dataset and analytical tools, which will be publicly accessible for querying to researchers for data mining and analysis.

The project also seeks to fill data gaps in the Knowledge Portal by both collecting new data and executing specific analyses. Researchers will investigate targets of particular interest by sequencing DNA from select individuals, incorporating the resulting new data into the common database. The end goal will be to have a powerful, publicly available T2D Knowledge Portal with a progressively growing database and analytical tools for identification and validation of effective T2D drug candidates. The 5-year, $40M project launched in early 2014.

To read the full project plan click here.

Current Funding Opportunities:

(Deadline has passed)

AMP T2D Request for Proposals 5

AMP T2D Request for Proposals 6

AMP T2D Request for Proposals 7

Instructions for Formatting:

Proposals should be limited to 25 pages (not including investigator curricula vitae, limited to 4 pages each in standard NIH format, and letters of support).  Please use 12 point font, single-spaced formatting with half-inch margins.

In addition to submission of a proposal, FNIH asks that each applicant include a completed “RFP Application Details Table”. This table is intended to help standardize the information found in submitted proposals.

Please complete and submit one table per proposal submission and note that each table consists of two tabs.

For additional information on the AMP T2D program and current funding opportunities, please reference the Frequently Asked Questions (FAQs).

Contact:

For additional information please contact David Wholley, Director of Research Partnerships, at dwholley@fnih.org or (301) 594-6343 

Related Resources:

NIH News Release (June 2016): Diabetes portal adds data, more powerful search tools

Accelerating Medicines Partnership expands reach, potential of type 2 diabetes engine

Press release: Accelerating Medicines Partnership Announces Awards to Advance Research in Type 2 Diabetes

AMP T2D Knowledge Portal

NIH Overview of Accelerating Medicines Partnership Type 2 Diabetes

Accelerating Medicines Partnership

Accelerating Medicines Partnership - Alzheimer's Disease

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systematic Lupus Erythematosus & Related Autoimmune Disorders

Partners:

American Diabetes Association, Janssen Research and Development LLC, Juvenile Diabetes Research Foundation, Eli Lilly and Company, Merck Sharp & Dohme Corp., Pfizer Inc., and Sanofi US Services